Bioventus expects 2026 revenue of $590M-$595M while reaffirming adjusted EPS of $0.75-$0.79
What it means
- What to watch: The headline zeroes in on a single EPS figure — but the real story lies in how that number stacks up against what investors were expecting.
- How the stock is trading: $BVS -1.31% in the latest session.
- Timing: It arrived overnight — the change beside it belongs to a session that had already packed up and gone home. Market holidays are not detected.
Where the stock stands
$BVS last traded at $13.15, -1.31% on the session. That puts it 17% shy of its 52-week high of $15.89 and 103% clear of its low of $6.47 — in the upper part of the range. Over the year it has ranged 146% from low to high: a very wide band; big swings are routine for this one, not news. These are latest-session quotes, not live prices — the live tape is on the $BVS page.
How much coverage it is getting
Nothing else on $BVS in the last 30 days: this is the only story Wook has filed, so there is no run to measure it against yet. 12 related stories from the same name or desk are listed beside this one.
The bigger picture
Earnings reports are less about the numbers and more about how they stack up against expectations — and how the guidance shapes the narrative. Wook's supply-chain scanner has Health Care reading calm today: no unusual stress in the filings and disclosures it watches.
Coming up
$BVS earnings today. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the hard numbers get the last word soon.
What to watch next
The $BVS page has the full chart, filings, and valuation model. Comparing coverage from different outlets is key to seeing if the story is confirmed or just echoed. Wook AI can pull live data and run the numbers on request — like how far $BVS is from its high or how this week's coverage stacks up.
How this analysis was made
Seeking Alpha published it, and Wook filed it under Earnings. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $BVS. It carried $590 million, $595 million, $0.75 and $0.79, shown as published and not recalculated. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.